02 May 2003 : Case report
Topical treatment with BGP-15M, a poly(ADP-ribose) polymerase inhibitor protects from ultraviolet radiation-induced skin cancer in vivoB. Farkas, M. Magyarlaki, B. Csete, S. Bernath
Med Sci Monit 2003; 9(1): 25- :: ID: 15075
Experimental data suggest that enzymes and substances, which decrease DNA-damage or improve repair can be used as photoprotective agents. These observations have led to the development of new strategies to facilitate DNA-repair in human cells and thereby improve photoprotection [1–3]. UV-irradiation may have deleterious effects on the DNA of skin cells. Indeed, UV-irradiation is capable of inducing extensive DNA-damage that overactivates PARP causing increased energy demand, which in turn may result in collapse of energy metabolism and in cell death. This suggests that moderation of PARP activity following DNA-damage may protect skin cells from the harmful effects of acute and chronic UV-exposure.The effects of BGP-15M, a topically applied novel PARP-inhibitor on UV-induced acute and chronic photodamage were investigated in a hairless mouse model and in human skin. DNA injury was detected by measuring the formation of single-strand DNA breaks and counting sunburn cells. The ADP-ribosylation of PARP was assessed by Western blot analysis. Immunosuppression was investigated in epidermal cells by detecting TNFá and IL-10 expression. UV-induced photocarcinogenesis was determined by clinical, immunohistochemical, and biochemical methods. It has been observed that BGP-15M protects against the clinical and histopathological signs of long-term (26 week) UVA exposure in 8-methoxipsoralen sensitized skin, and decreases the UVB-induced accumulation of mutations and deletions in tumor suppressor genes. Topical treatment with BGP-15M prevents photocarcinogenesis induced by long-term, 32 week-UVB or 26 week-UVA exposure in hairless mice. The above observations carry the promise of a novel type biological skin protective agent against UV-induced photocarcinogenesis, which can revolutionize sun protection in the coming years. References: 1.Yarosh D et al: Lancet, 2001; 357: 926 2.Farkas B et al: Biochem Pharmacol, 2002; 63: 921 3.Farkas B et al: Pharmacology & Toxicology Series, Boca Raton, London, Washington, CRC Press 2002; pp: 257
Keywords: topical PARP-inhibitor, skin cancer, UVA, UVB, photoprotection
01 May 2023 : EditorialEditorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy
Med Sci Monit 2023; 29:e940911
31 May 2023 : Review articlePrevalence, Diagnosis, and Management of Eclampsia and the Need for Improved Maternal Care: A Review
Med Sci Monit In Press; DOI: 10.12659/MSM.939919
30 May 2023 : Clinical ResearchA Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodi...
Med Sci Monit In Press; DOI: 10.12659/MSM.940409
30 May 2023 : Review articleA Review of the Role of the Zebrafish (Danio reiro) in Preclinical and Clinical Models of Biomarker Identif...
Med Sci Monit In Press; DOI: 10.12659/MSM.940550
30 May 2023 : Database AnalysisThe COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in Poland
Med Sci Monit In Press; DOI: 10.12659/MSM.940904
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...
Med Sci Monit 2022; 28:e935952